Vec­talys and Flash­Cell merge in­to Flash Ther­a­peu­tics, loaded with RNA pipeline and man­u­fac­tur­ing set-up

Two gene ther­a­py com­pa­nies in France are merg­ing to cre­ate one ven­ture called Flash Ther­a­peu­tics, com­bin­ing man­u­fac­tur­ing know-how with a pipeline of RNA drug prospects.

The merg­er is be­tween Vec­talys, a Toulouse-based mak­er of lentivi­ral vec­tors, and its spin­out start­up Flash­Cell, which launched out of Vec­talys just last year to tack­le RNA car­ri­ers for drug ap­pli­ca­tions.

The CEO of the com­bined com­pa­ny, Pas­cale Bouil­lé, tells me the merg­er part­ly came down to bio­man­u­fac­tur­ing in­dus­tri­al log­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER